Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Insulet Corporation

Market Cap 10.49B 9.09B 8.34B 7.85B 14.61B 1,000B 14.84B 99.12B 38.58B 484B 39.4B 38.55B 1,682B P/E ratio 2026 *
24.4x
P/E ratio 2027 * 18.9x
Enterprise value 10.57B 9.16B 8.4B 7.91B 14.72B 1,008B 14.96B 99.88B 38.87B 487B 39.71B 38.84B 1,695B EV / Sales 2026 *
3.18x
EV / Sales 2027 * 2.59x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day-1.12%
1 week+2.28%
Current month+4.53%
1 month-1.72%
3 months-36.07%
6 months-48.85%
Current year-46.70%
1 week 141.45
Extreme 141.45
154.71
1 month 140.63
Extreme 140.63
160.07
Current year 140.63
Extreme 140.63
299.8
1 year 140.63
Extreme 140.63
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 27.62
Extreme 27.6201
354.88
Manager TitleAgeSince
Chief Executive Officer 55 27/04/2025
Director of Finance/CFO 53 29/09/2025
Compliance Officer 50 30/11/2022
Director TitleAgeSince
Chairman 61 31/12/2018
Director/Board Member 61 26/07/2015
Director/Board Member 59 09/08/2017
Date Insider Type Main position Quantity % Market Cap.
06-02Buy

Director

3,450 0.0049%
06-02Buy

Director

2,790 0.0040%
06-02Sell

Director

-418 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%+2.28%-51.40%-46.15% 10.49B
-0.63%+3.10%-32.25%-10.20% 158B
-1.20%+9.07%-7.72%-2.90% 104B
+1.29%-2.66%+53.23%+49.61% 52.82B
-0.35%+3.55%-5.14%+55.33% 53.33B
-0.77%+3.21%-13.53%-39.88% 41.33B
+0.57%-5.45% - - 28.58B
+5.16%+2.34%-11.60%-36.75% 29.57B
+1.67%+1.09%+42.31%-8.58% 22.59B
-0.02%+1.58%-12.56%+3.07% 21.03B
Average +0.83%+0.71%-4.30%-4.05% 52.1B
Weighted average by Cap. +0.96%+2.43%-8.32%+0.64%

Financials

2026 *2027 *
Net sales 3.32B 2.88B 2.64B 2.48B 4.63B 317B 4.7B 31.39B 12.22B 153B 12.48B 12.21B 533B 3.94B 3.41B 3.13B 2.95B 5.49B 376B 5.57B 37.22B 14.49B 182B 14.8B 14.48B 632B
Net income 432M 374M 343M 323M 602M 41.18B 611M 4.08B 1.59B 19.91B 1.62B 1.59B 69.25B 567M 491M 450M 424M 789M 53.99B 801M 5.35B 2.08B 26.11B 2.13B 2.08B 90.79B
Net Debt 80.64M 69.83M 64.07M 60.28M 112M 7.68B 114M 762M 296M 3.72B 303M 296M 12.92B -289M -250M -229M -216M -402M -27.52B -408M -2.73B -1.06B -13.31B -1.08B -1.06B -46.28B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
08/06/26 151.51 $ -1.12% 1,569,646
05/06/26 153.22 $ +4.65% 2,307,440
04/06/26 146.41 $ +2.17% 1,410,455
03/06/26 143.30 $ +0.61% 1,140,980
02/06/26 142.43 $ -3.85% 1,121,247
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
151.51USD
Average target price
243.78USD
Spread / Average Target
+60.90%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW